Brolucizumab

Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights

Retrieved on: 
Wednesday, March 27, 2024
Brolucizumab, Sale, Acquisition, Conjugation, Cancer, Antibody, Therapy, ADC, Antibody-drug conjugate

BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rights to royalties from the commercialization of Beovu® (brolucizumab-dbll) and another asset to Novartis for a one-time cash payment of $8 million.

Key Points: 
  • Under the agreement with Novartis, Pyxis Oncology will receive an $8 million payment from Novartis.
  • Royalties previously received by Apexigen and Pyxis Oncology will be free from any reclaim rights.
  • Pyxis Oncology will record the $8 million payment in Q1 2024.
  • Pyxis Oncology retains rights to three other antibodies in development by Apexigen's licensees, which were also discovered leveraging the APXiMAB platform.

PulseSight Therapeutics Launches to Advance Non-viral Gene Therapies with Disruptive Minimally-Invasive Delivery Technology for Severe Retinal Diseases

Retrieved on: 
Wednesday, February 28, 2024
Doctor of Philosophy, Decorin, Drug development, Sale, Iris (anatomy), Transferrin, Ciliary muscle, Geographic atrophy, Ranibizumab, Iron, Retinitis pigmentosa, Retina, CNV, Paratriathlon, Eye, Brolucizumab, VEGF, Therapy, AMD, Independent, DNA, Retinal pigment epithelium, KIP, Doctor of Pharmacy, Safety, Novartis, Oxidative stress, CSO, Conditional sentence, RPE, EMA, MD, FDA, SAS, Choroidal neovascularization, Cell, Human, Patient, Glaucoma, Gene expression

Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.

Key Points: 
  • Unique proprietary non-viral gene therapy platform with minimally invasive delivery technology providing long lasting gene expression and favorable distribution in the retina.
  • A substantially de-risked platform and two first-in-class gene therapies heading to the clinic, having the potential to become future blockbusters.
  • PARIS, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral gene therapies with minimally-invasive delivery technology, launches today with seed finance from Pureos Bioventures and ND Capital.
  • PulseSight is currently raising a Series A financing round to advance its programs into clinical proof-of-concept.

Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs

Retrieved on: 
Wednesday, April 26, 2023
Heart, Drug development, Senior, DME, Bausch, OCS, Bausch & Lomb, Latanoprostene bunod, Novartis, Alcon, MD, Ophthalmology, Regulatory affairs, FDA, Brolucizumab, Pharmaceutical industry, Inflammation, Pain, In ictu oculi

The expansion of Oculis’s presence in the US accompanies the recent strengthening of its finance and development team.

Key Points: 
  • The expansion of Oculis’s presence in the US accompanies the recent strengthening of its finance and development team.
  • This includes the hiring of Dr. Fang Li as the new US-based Senior Vice President, Regulatory Affairs.
  • Dr. Li brings to Oculis over 25 years of drug development experience, having worked in regulatory affairs for over 20 years with leading ophthalmology companies such as Novartis, Alcon and Bausch & Lomb, among others.
  • She has extensive experience with health authority interactions, FDA advisory committee meeting preparation, and building and leading regulatory teams.

Diabetic Retinopathy Pipeline Research Report 2022: Featuring Insights on 60+ Companies and Drugs in the Sector - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 8, 2023
Pharmaceutical, Health, Optical, Route, Physician, Diabetic retinopathy, News, Edema, VEGF, Growth, Clinical trial, Fragment crystallizable region, Discovery, Injection, Administration, Anti-VEGF, AMD, NAV, Patient, Therapy, Ischemia, Drug development, Route of administration, Cerebral edema, GameChanger, Branch retinal vein occlusion, Pharmaceutical industry, Vaccine, Brolucizumab

Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.

Key Points: 
  • Anti-VEGF agents have become a very common treatment to improve the clinical outcomes in patients with diabetic retinopathy.
  • This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.
  • The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e.
  • Phase III include, Kodiak Sciences
    Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Age-Related Macular Degeneration (AMD) Global Market Report 2022: Upcoming Treatments to Redefine Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
General Health, Health, Optical, Macular degeneration, Insurance, Pharmacy, Paratriathlon, CVS Caremark, Intravitreal administration, Anti-VEGF, Projection, 2052: A Global Forecast for the Next Forty Years, Medicare, Market, AMD, Incidence, Eye, Ageing, UNDESA, Retina, Research, Bevacizumab, Visual impairment, American Ophthalmological Society, Vance DeGeneres, Research report, VEGF, Hospital, Disease, FDA, Luminate, Investment, Macular edema, US, Publishing, Pharmaceutical industry, Sales, Growth, Brolucizumab

Dry macular and wet macular degeneration are the two main types of macula wear and tear leading to the disorder.

Key Points: 
  • Dry macular and wet macular degeneration are the two main types of macula wear and tear leading to the disorder.
  • The potential market for the treatment of age-related macular degeneration is growing in response to rising demand from the elderly.
  • Furthermore, an increase in the occurrence of eye-related disorders and growth in the global elderly population drives the age-related macular degeneration market.
  • In addition, the rising market trends, such as the advancement of gene therapy for age-related macular degeneration, will lead to the development of medical treatment for age-related macular degeneration.

Age-Related Macular Degeneration (AMD) Global Market Report 2022: Sector to Reach $14.6 Billion by 2028 at an 8.5% CAGR

Retrieved on: 
Wednesday, January 25, 2023
Vance DeGeneres, Research report, Investment, VEGF, Macular degeneration, Anti-VEGF, UNDESA, Hospital, Visual impairment, Incidence, Retina, Medicare, Paratriathlon, US, Pharmacy, Insurance, Ageing, FDA, CVS Caremark, Macular edema, 2052: A Global Forecast for the Next Forty Years, Eye, Intravitreal administration, AMD, American Ophthalmological Society, Disease, Luminate, Research, Distribution, Bevacizumab, Projection, Publishing, Pharmaceutical industry, Sales, Brolucizumab, Growth

Age-Related Macular Degeneration Market will reach US$ 14.06 Billion in 2028 according to the publisher.

Key Points: 
  • Age-Related Macular Degeneration Market will reach US$ 14.06 Billion in 2028 according to the publisher.
  • Dry macular and wet macular degeneration are the two main types of macula wear and tear leading to the disorder.
  • As per our research findings Age-related Macular Degeneration Industry will expand at a CAGR of 8.5% from 2022 to 2028.
  • Furthermore, an increase in the occurrence of eye-related disorders and growth in the global elderly population drives the age-related macular degeneration market.

Age-related Macular Degeneration Global Market Report 2022: Surging Prevalence of Retinal Disorders Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 16, 2023
Pharmaceutical, Health, Optical, Disease, Administration, Statistics, Intravitreal injection, Government, FDA, AMD, Projection, U.S. FDA, Growth, Region, Patient, Prevalence, Brolucizumab, American Academy of Ophthalmology, Macular degeneration, American Academy, Pharmacy, Biogen, Central retinal vein occlusion, Inflammation, Incidence, USD, Market share, Investment, Pharmaceutical industry, Generic drug, Ranibizumab, Ophthalmology, EU

Increasing R&D investments, expanding geriatric population, surging number of people with retinal disorders, product launch and approval, and medicines for the treatment of dry AMD are factors contributing to the market growth.

Key Points: 
  • Increasing R&D investments, expanding geriatric population, surging number of people with retinal disorders, product launch and approval, and medicines for the treatment of dry AMD are factors contributing to the market growth.
  • Surging number of people with retinal disorders is expected to stimulate the market growth.
  • According to statistics, the market expansion is significantly associated with the rising number of people suffering from retinal problems.
  • Thus, the growing prevalence of these conditions is fuelling demand for macular degeneration treatments, which is further boosting market growth.

Diabetic Retinopathy Drug Pipeline Market Insights Report 2022 - Comprehensive Insights About 60+ Companies and 60+ Pipeline Drugs - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Diabetes, Health, Other Health, Diabetic retinopathy, Clinical trial, Injection, NAV, Route, News, Route of administration, Drug development, Branch retinal vein occlusion, Discovery, II, Edema, Cerebral edema, Ischemia, Fragment crystallizable region, Administration, VEGF, Physician, Therapy, Growth, AMD, GameChanger, Patient, Oil, Pharmaceutical industry, Brolucizumab

This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape.

Key Points: 
  • This report provides comprehensive insights about 60+ companies and 60+ pipeline drugs in Diabetic Retinopathy pipeline landscape.
  • This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • The companies which have their Diabetic Retinopathy drug candidates in the mid to advanced stage, i.e.
  • Phase III include, Kodiak Sciences
    Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Verana Health to Present Findings of Studies Using American Academy of Ophthalmology IRIS® Registry Data to Advance Insights into Real World Outcomes in Treating AMD

Retrieved on: 
Wednesday, November 2, 2022
Millennium, American Academy, MD, NAMD, Blood, Retinal degeneration (rhodopsin mutation), Durability, Doctor of Philosophy, Brolucizumab, Geographic atrophy, Machine Intelligence Research Institute, HCPS, American Academy of Ophthalmology, Research, AMD, Patient, RWD, Comparison, VEGF, Department, Varnaq, Data management, American Academy of Neurology, Academy, Rush University Medical Center, CATT, HCP, Medicine, Novartis, FDA, American Urological Association, IgG4-related ophthalmic disease, Clinical trial, Poster, Severe cognitive impairment, SAN, Quality of life, Solution, Pharmaceutical industry, Medical imaging, Ophthalmology

SAN FRANCISCO, Nov. 2, 2022 /PRNewswire/ -- During The Retina Society's 55th Annual Scientific Meeting Nov. 2 to 5, Verana Health®—a digital health company elevating quality in real-world data—will present findings on two separate studies that utilize curated real-world data (RWD) from the American Academy of Ophthalmology (Academy) IRIS® Registry (Intelligent Research in Sight).

Key Points: 
  • treatment arms of the CATT trial using de-identified IRIS Registry data from a real-world population to compare treatment outcomes at one year to the monthly treatment arms of the CATT using patient-level clinical trial data.
  • Established in 2014, the IRIS Registry is one of the largest specialty society clinical data registries in all of medicine.
  • Using its clinician-informed and artificial intelligence-enhanced VeraQpopulation health data engine, Verana Health transforms structured and unstructured healthcare data into curated, disease-specific data modules, Qdata.
  • Verana Health's quality data and insights help drive progress in medicine to enhance the quality of care and quality of life for patients.

US Ophthalmologists Report Increasing Trial of Roche/Genentech's Vabysmo in Diabetic Macular Edema, Though Regeneron's Eylea Maintains Its Strong Positioning, According to Spherix Global Insights

Retrieved on: 
Wednesday, October 12, 2022
Pressure, Alimera Sciences, Brolucizumab, Ophthalmology, Patient, Diabetic retinopathy, Samsung, Novartis, Awareness, AbbVie, Bevacizumab, FDA, Nephrology, Regeneron Pharmaceuticals, Pharmaceutical industry, Medical device, Generic drug, DME, NAMD, Dexamethasone, Genentech, Ranibizumab

EXTON, Pa., Oct. 12, 2022 /PRNewswire/ -- Now on the market for over nine months, Roche/Genentech's Vabysmo (faricimab-svoa) has had success in expanding the breadth of users. However, depth of use is limited and has translated to minimal market share to date in diabetic macular edema (DME). The latest quarterly report included in Spherix's RealTime Dynamix™ service offered in DME captured feedback from 101 US ophthalmologists on their use and perceptions of both in-line and pipeline assets in this rapidly changing market.

Key Points: 
  • However, depth of use is limited and has translated to minimal market share to date in diabetic macular edema (DME).
  • Unsurprisingly, Eylea continues to dominate the space and has even shown a slight increase in brand share over the year, despite the added pressure from Vabysmo.
  • On the other hand, Novartis' latest launch for Beovu in DME is also off to a slow start.
  • AbbVie/Allergan's Ozurdex and Alimera Science's Iluvien, already reserved for later-line patients, have continued to lose ground in the DME market.